Five investigational therapeutics have been approved by the Democratic Republic of the Congo for the treatment Ebola Virus Disease.
This is the first time such treatments would be available as the disease resurfaced in the country.
The World Health Organization (WHO) has said that four of the five approved drugs are presently in the Central African nation.
According to WHO, these drugs include Zmapp, GS-5734, REGN monoclonal antibody combination, and mAb114, under the framework of compassionate use and expanded access.
Concise News gathered that clinicians working in the treatment centres will make decisions on which drug to use as deemed helpful for their patients, and appropriate for the setting.
Also, the treatments can be used as long as informed consent is gotten from patients and protocols are followed, with close monitoring and reporting of any negative effects.